Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

What Was Tested

The paper reports a study of Insulin Glargine, published as a randomized controlled trial.

A medical need remains for a once-daily insulin with 24-h basal coverage in all patients.

Who Took Part

The study group was 66 patients.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

The patients were allocated by chance, so the Insulin Glargine group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Insulin Glargine.

In the crossover set-up each of the patients took both Insulin Glargine and the comparison in turn, acting as their own control.

Glucose infusion rate (GIR), distribution of GIR and half-life were assessed.

What Was Measured

Topics PubMed links to this paper include Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 1, Glucose Clamp Technique, Half-Life, Hypoglycemic Agents and Insulin Glargine.

Author keywords: euglycemic glucose clamp, insulin degludec and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Glargine in 66 patients.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Expert opinion on drug metabolism & toxicology), a journal based in England.

More context: the Insulin Glargine compound page, all human trials.